全球每年有数千万人受到颅脑创伤的影响，至今仍缺乏有效的治疗方法。先前的研究发现颅脑创伤会导致线粒体心磷脂损伤重塑，其中包含氧化、水解、酰基转移等过程，脂质氧化代谢和脂质修复将影响到远期神经功能恢复预后。我们认为完整的描绘出线粒体脂质氧化代谢（尤其是心磷脂）在外伤后的变化，干预脂质氧化重塑过程，上调重塑过程中的Tafazzin（Taz）、减少其在线粒体中降解有助于神经细胞线粒体膜磷脂修复，最终有助于脑功能恢复。本项目拟通过细胞与动物颅脑创伤模型，利用相关质谱技术分析绘制外伤后不同时间点及部位的脂质质谱脑功能全图，同时检测脂质氧化重塑相关蛋白表达水平，并尝试干预线粒体蛋白酶减少Taz降解，在基因调控动物实验中验证Taz对脑外伤预后恢复的作用。本项目研究成果将有助于全面认知颅脑外伤后脂质及其氧化水解重塑代谢物的病理生理过程，有助于线粒体磷脂修复的靶向药物开发，并为脑外伤药物治疗方案提供理论。

Tens of millions of people are influenced by traumatic brain injury per year globally, and there is still no effective therapy by now. In previous studies, it is found that craniocerebral trauma will result in cardiolipin injury and remodeling, including oxidation, hydrolysis, acyl transfer and other processes, oxidative metabolism of lipid and lipid repair will influence the long-term neural function recovery prognosis. We think that complete description of changes to oxidative metabolism of cardiolipin after trauma, the process of intervention in lipid oxidation and remodeling, up-regulation of Tafazzin (Taz) during remodeling and reduction of degradation in mitochondria are helpful for the repair of neurocyte mitochondrial membrane phospholipid, and finally helpful for brain function recovery. This project, through cell and animal craniocerebral trauma models, aims to utilize related mass spectrum technologies to analyze and draw lipid mass spectrum brain function total graphs at different time points and in different parts and to detect the expression levels of proteins related with lipid oxidation and remodeling at the same time, and attempts to intervene mitochondrial protease’s reduction of Taz degradation and prove the role of Taz for brain trauma prognosis and recovery in the gene regulation animal experiment. The research results of this project will be helpful for complete understanding of the pathophysiological process of lipid and oxydrolysis remodeling metabolites after craniocerebral trauma, be helpful for development of targeted drugs for cardiolipin repair, and provide theoretical guidance for brain trauma drug therapy schemes.